5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use

• US 4,666,908 A
• Filed: 04/05/1985
• Issued: 05/19/1987
• Est. Priority Date: 04/05/1985
• Status: Expired due to Fees

• Current Assignee: Warner-Lambert Company (Pfizer Inc.)
• Original Assignee: Warner-Lambert Company (Pfizer Inc.)
• Inventors: Hamilton, Harriet W.
• Primary Examiner(s): Rosen, Sam
• Assistant Examiner(s): NOT, DEFINED
• Application Number:
  US06/720,437
• Time in Patent Office: 774 Days
• Field of Search: 544/262, 544/118, 514/258, 514/234, 514/229
• US Class Current: 514/234.2
• CPC Class Codes: A61P 9/04 Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
• CPC Class Codes: C07D 487/04 Ortho-condensed systems

Abstract

The present invention relates to novel 5-substituted pyrazolo[4,3-d]pyrimidine-7-one compounds, and compositions, methods of use and processes to make therefor. The novel compounds are useful in the treatment of cardiovascular disorders, such as heart failure or cardiac insufficiency. The novel compounds bind adenosine receptors and selectively inhibit phosphodiesterase.

Claims

1. A compound of the formula ##STR8## wherein R₁ is lower alkyl of from one to six carbons, inclusive, lower alkenyl of from two to six carbons, inclusive, lower hydroxyalkyl of from one to six carbons, inclusive, lower hydroxyalkenyl of from two to six carbons, inclusive, dimethylaminoethyl or lower amino alkenyl of from two to six carbons, inclusive;

n is 0-4; and

Ar is ##STR9## or 2, 3, or 4-pyridyl, wherein X, Y, and Z are independently (1) hydrogen;

(2) lower alkyl of from one to six carbons, inclusive;

(3) halogen;

(4) hydroxyl;

(5) lower alkoxy of from one to six carbons, inclusive;

(6) nitro;

(7) amino;

(8) NR'"'"'R" wherein R'"'"' and R" are each independently (a) hydrogen or (b) lower alkyl of from one to six carbons, inclusive, optionally substituted by (i) amino, (ii) morpholino or (iii) cycloalkyl of from five to seven carbons, inclusive;

(9) sulfo;

or (10) --SO₂ NR'"'"'R" wherein R'"'"' and R" are as defined above with the proviso that not all of X, Y, and Z can be nitro, amino, or NR'"'"'R" at once; and

pharmaceutically acceptable salts thereof.

2. A compound of claim 1 wherein Ar is R₂ and n is 0.

3. A compound of claim 1 wherein Ar is 2-, 3-, or 4-pyridyl.

4. A compound of claim 1 wherein Ar is R₂, R₁ is methyl and n is 1.

5. A compound of claim 2 wherein the embodiment is 1-ethyl-3-methyl-5-phenylpyrazolo[4,3-d]pyrimidine-7-one.

6. A compound of claim 3 wherein the embodiment is 1,3-dimethyl-5-(3-pyridyl)pyrazolo[4,3-d]pyrimidine-7-one.

7. A compound of claim 2 wherein the embodiment is 1,3-dimethyl-5-phenylprazolo[4,3-d]pyrimidine-7-one.

8. A compound of claim 4 wherein the embodiment is 1,3-dimethyl-5-benzylpyrazolo[4,3-d]pyrimidine-7-one.

9. A compound of claim 2 wherein the embodiment is 1,3-dimethyl-5-(4-chlorophenyl)pyrazolo[4,3-d]pyrimidine-7-one.

10. A compound of claim 2 wherein the embodiment is 1,3-dimethyl-5-(4-methylphenyl)pyrazolo[4,3-d]pyrimidine-7-one.

11. A compound of claim 2 wherein the embodiment is 1,3-dimethyl-5-(4-nitrophenyl)pyrazolo[4,3-d]pyrimidine-7-one.

12. A compound of claim 2 wherein the embodiment is 1,3-dimethyl-5-(4-trifluoromethylphenyl)pyrazolo[4,3-d]pyrimidine.

13. A compound of claim 2 wherein the embodiment is 1,3-dimethyl-5-(4-aminophenyl)pyrazolo[4,3-d]pyrimidine-7-one.

14. A compound of claim 2 wherein the embodiment is 1,3-dimethyl-5-(3-aminophenyl)pyrazolo[4,3-d]pyrimidine-7-one.

15. A compound of claim 2 wherein the embodiment is 1,3-dimethyl-5-(3-nitrophenyl)pyrazolo[4,3-d]pyrimidine-7-one.

16. A compound of claim 2 wherein the embodiment is 1,3-dimethyl-5-(2-methoxyphenyl)pyrazolo[4,3-d]pyrimidine-7-one.

17. A compound of claim 2 wherein the embodiment is 1,3-dimethyl-5-(3,4-dichlorophenyl)pyrazolo[4,3-d]pyrimidine-7-one.

18. A compound of claim 2 wherein the embodiment is 1,3-dimethyl-5-(3,4-dimethoxyphenyl)pyrazolo[4,3-d]pyrimidine-7-one.

19. A compound of claim 2 wherein the embodiment is 1,3-dimethyl-5-(2,4-dimethoxyphenyl)pyrazolo[4,3-d]pyrimidine-7-one.

20. A compound of claim 2 wherein the embodiment is 1,3-dimethyl-5-(2-nitro-4-chlorophenyl)pyrazolo[4,3-d]pyrimidine-7-one.

21. A compound of claim 2 wherein the embodiment is 1,3-dimethyl-5-(2-amino-4-chlorophenyl)pyrazolo[4,3-d]pyrimidine-7-one.

22. A compound of claim 2 wherein the embodiment is 1,3-dimethyl-5-(4-sulfophenyl)pyrazolo[4,3-d]pyrimidine-7-one.

23. A compound of claim 4 wherein the embodiment is 1-ethyl-3-methyl-5-benzylpyrazolo[4,3-d]pyrimidine-7-one.

24. A compound of claim 2 wherein the embodiment is 1,3-dimethyl-5-(3,5-dimethoxyphenyl)pyrazolo[4,3-d]pyrimidine-7-one.

25. A compound of claim 2 wherein the embodiment is 1,3-dimethyl-5-(3-methoxyphenyl)pyrazolo[4,3-d]pyrimidine-7-one.

26. A compound of claim 3 wherein the embodiment is 1,3-dimethyl-5-(2-pyridyl)pyrazolo[4,3-d]pyrimidine-7-one.

27. A pharmaceutical composition for treating cardiac insufficiency comprising a cardiotonic effective amount of a compound according to claim 1 in admixture with a pharmaceutically acceptable carrier.

28. A method for treating cardiac insufficiency in a mammal suffering therefrom comprising administering to such mammal a compound as claimed in claim 1 in unit dosage form.

29. A compound of claim 3 wherein the embodiment is 1-ethyl-3-methyl-5-(4-pyridyl)pyrazolo[4,3-d]pyrimidine-7-one.

30. A compound of claim 3 wherein the embodiment is 1,3-dimethyl-5-(4-pyridyl)pyrazolo[4,3-d]pyrimidine-7-one.

31. A compound of claim 2 wherein the embodiment is 4-(6,7-dihydro-1,3-dimethyl-7oxo-1H-pyrazolol[4,3-d]pyrimidin-5-yl)-N-[2-(dimethylamino)ethyl]benzenesulfonamide.